Want to see IN:NOVARTIND full AI Analyst Report?

Novartis India Limited (NOVARTIND) Price & Analysis

― Followers

NOVARTIND Stock Chart & Stats

₹1966.70

-₹1.15(-0.06%)

Oct 05, 2026

―

Day’s Range― - ―

52-Week Range₹750.00 - ₹2,588.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)16.57K

Market Cap

₹48.59B

Enterprise Value₹17.40B

Total Cash (Recent Filing)₹6.68B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)49.7

Beta0.07

Next Earnings

Nov 03, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield1.27%

Share Statistics

EPS (TTM)39.61

Shares Outstanding24,690,796

10 Day Avg. Volume4,851

30 Day Avg. Volume16,574

Financial Highlights & Ratios

PEG Ratio-3.36

Price to Book (P/B)2.93

Price to Sales (P/S)6.76

P/FCF Ratio28.41

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Very Low Financial LeverageAn almost debt-free balance sheet materially reduces financial risk and interest-related pressure on earnings. It gives Novartis India flexibility to sustain operations, fund commercialization, and absorb weaker periods without depending heavily on refinancing or additional borrowing.

Strong Recent ProfitabilitySustained mid-20% net margins across recent years indicate that the branded pharmaceutical commercialization model is currently producing meaningful earnings. Strong profitability can support reinvestment in market coverage and provide resilience against moderate revenue fluctuations.

Good Recent Free Cash FlowRecent free cash flow broadly converting reported profits into cash strengthens the quality of earnings and supports internally funded operations. Strong cash generation also gives the company greater capacity to maintain distribution activities and pursue commercial priorities without leverage.

Bears Say

Uneven Revenue GrowthThe uneven revenue trajectory shows that growth has not been consistently established across the full period. Although the latest rebound is encouraging, repeated declines can make planning less predictable and may limit confidence that recent momentum will translate into durable expansion.

Volatile Cash-flow HistoryRecent cash generation is solid, but the broader history shows material swings in operating and free cash flow. Such variability can weaken the reliability of internal funding, making it harder to plan investment, distributions, or commercial spending through changing business conditions.

Dependence On Novartis Group StrategyReliance on Novartis AG’s product portfolio and strategic decisions means local commercial opportunities are not fully controlled by Novartis India. Changes in group priorities, marketed therapies, or operating arrangements could therefore affect the company’s longer-term revenue base.

NOVARTIND FAQ

What was Novartis India Limited’s price range in the past 12 months?

Novartis India Limited lowest stock price was ₹750.00 and its highest was ₹2588.00 in the past 12 months.

What is Novartis India Limited’s market cap?

Novartis India Limited’s market cap is ₹48.59B.

When is Novartis India Limited’s upcoming earnings report date?

Novartis India Limited’s upcoming earnings report date is Nov 03, 2026 which is in 28 days.

How were Novartis India Limited’s earnings last quarter?

Novartis India Limited released its earnings results on Jul 23, 2026. The company reported ₹13.045 earnings per share for the quarter.

Is Novartis India Limited overvalued?

According to Wall Street analysts Novartis India Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Novartis India Limited pay dividends?

Novartis India Limited pays a Annually dividend of ₹25 which represents an annual dividend yield of 1.27%. See more information on Novartis India Limited dividends here

What is Novartis India Limited’s EPS estimate?

Novartis India Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Novartis India Limited have?

Novartis India Limited has 24,690,796 shares outstanding.

What happened to Novartis India Limited’s price movement after its last earnings report?

Novartis India Limited reported an EPS of ₹13.045 in its last earnings report. Following the earnings report the stock price went down -1.772%.

Which hedge fund is a major shareholder of Novartis India Limited?

Currently, no hedge funds are holding shares in IN:NOVARTIND

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Novartis India Limited

Novartis India Limited, an Indian healthcare enterprise, provides a diverse range of pharmaceutical solutions. Its offerings include branded medications for conditions related to bone and pain management, calcium supplementation, women's health (gynecology), and neurological disorders. Furthermore, the company supplies generic drugs specifically for gynecological issues, anti-tuberculosis treatments, and anti-infective applications. Notable branded products within its portfolio comprise Tegrital and Exelon for central nervous system disorders, Voveran for pain and inflammation relief, and specialized transplantation/immunology drugs like Simulect, Certican, Myfortic, and Sandimmun Neoral. Established in 1947 and headquartered in Mumbai, India, Novartis India Limited operates as a subsidiary of Novartis AG.